Fractyl's Revita Procedure Maintains 78% GLP-1 Weight Loss in One-Year Study
GUTS has more than doubled off its 52-week low of $0.377.
Summary
Fractyl Health reported positive one-year results from its Reveal-1 open-label study for the Revita procedure, showing sustained weight maintenance after GLP-1 discontinuation. Patients maintained 78% of their GLP-1-induced weight loss, with a mean weight change of 5.3% observed at one year, and no procedure-related serious adverse events. This news follows an 8-K filed today disclosing the same results and provides a much-needed positive development for the company, which recently received a Nasdaq bid price deficiency notice and issued a 'going concern' warning in its latest 10-Q.
At the time of this announcement, GUTS was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $120.6M. The 52-week trading range was $0.38 to $3.03. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.